Ammonium Chloride
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Ammonium Chloride
- Pharmacist Assessment Report
- Ammonium Chloride: From Pharyngitis, Common Cold and Nasopharyngitis to Nasal Cavity Disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Ammonium Chloride: From Pharyngitis, Common Cold and Nasopharyngitis to Nasal Cavity Disease
One-Sentence Summary
Ammonium chloride is an ingredient in cough and cold syrups. The TxGNN model predicts it may be effective for nasal cavity disease, but at present there are 0 clinical trials and 0 publications supporting this direction, so this is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pharyngitis, common cold, nasopharyngitis (relations recorded in the knowledge graph; the Canadian licence records contain no indication text) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9994 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ammonium chloride is used in cough and cold syrups. Mechanistically, it may be applicable to nasal cavity disease through thinning of mucus and clearance of secretions.
This link is plausible but unverified. No clinical or mechanistic data were compiled to support it for nasal cavity disease specifically. The predicted indication is also broad. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02245592 | DAMYLIN WITH CODEINE SYRUP | Not listed | Not listed |
| 00690074 | COUGH SYRUP | Not listed | Not listed |
| 00535230 | CALMYLIN | Not listed | Not listed |
All three are valid licences. The licence records compiled for this report contain no indication text.
Safety Considerations
- Contraindications (relations recorded in the knowledge graph, not label text): The knowledge graph links ammonium chloride to many conditions, including:
- Cardiovascular: hypertension, sudden cardiac arrest, heart conduction disease, myocardial ischemia, coronary artery disease, pulmonary edema
- Liver and kidney: liver failure, impaired renal function, anuria, nephrocalcinosis
- Metabolic and endocrine: hypercalcemia, phosphorus metabolism disease, adrenocortical insufficiency, Addison disease, hyperthyroidism, Graves disease, thyrotoxicosis
- Eye: angle-closure glaucoma, ocular hypertension
- Neuropsychiatric: epilepsy, insomnia, anxiety disorder, agoraphobia, obsessive-compulsive disorder
- Other: peptic ulcer disease, benign prostatic hyperplasia, bladder neck obstruction, necrotizing enterocolitis
- Drug Interactions: 21 interactions were found.
- Moderate: amphetamine, benzphetamine, dextroamphetamine, lisdexamfetamine, metamfetamine
- Minor (examples): ephedrine, pseudoephedrine, methadone, mexiletine, flecainide, and tricyclic antidepressants (amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine)
Label warnings and contraindications from the Canadian package inserts were not available. Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, but no clinical trials or publications address nasal cavity disease, so the evidence level is L5. The predicted indication is broad, and label safety data are missing.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (to be downloaded and reviewed)
- Mechanism of action data (for example, from DrugBank)
- Indication text for the three Canadian licences
- A literature and trial search specific to nasal cavity disease
- Clarification of which specific nasal conditions are being targeted, and route and formulation compatibility
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.